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INTRODUCTION
Diabetes mellitus and the kidney
It is known that diabetic nephropathy constitutes a major
medical problem. In the past several years, the number of
diabetic patients in end-stage programs has been increasing,
more so in the United States [1] than in Europe [21. Presently,
the prognosis for uremic diabetic patients does not appear to
differ markedly from that of comparable nondiabetic uremics, at
least in some of the major centers, judged by presentations at
the Second Diabetic Renal-Retinal Syndrome meeting in New
York, November 1981 [3].
During the last decade, research in the field of diabetic renal
changes has been very active, especially regarding early
changes, and has aimed at clarification of the natural history
and elucidation of pathogenetic mechanisms and risk factors.
The present state of our knowledge utilizing morphological,
biochemical, physiological, and clinical methodologies appears
in this issue. To a certain extent, it represents an extension of
another Symposium issue, that reported on a workshop held in
Copenhagen 2 years ago [4].
Not surprisingly, attention was long directed mainly toward
the Kimmelstiel-Wilson syndrome and other long-term aspects
of kidney disease in diabetes mellitus [5, 6]. Later it appeared
that changes of seemingly another nature were demonstrable
during the initial phase of the disease [7—9]. By now the concept
of an early kidney hypertrophy-hyperfunction syndrome is well
established as the initial expression of renal involvement in
diabetes mellitus, followed by the stages shown in Table 1 and
Figure 1. The sketch illustrates the natural history of renal
changes in diabetes mellitus.
The implementation of the simple and very precise morpho-
metric techniques in clinical and experimental kidney research
now provides answers to a greater number of refined questions
regarding mechanisms and the course of the early diabetic
glomerular changes, in the same manner that these methods
have provided answers to crucial questions regarding long-term
diabetic microangiopathy and glomerulopathy. However, one
major problem is still unsolved: Are the early changes causally
related to the serious long-term nephropathy developing in as
many as approximately 35% of patients with insulin-dependent
diabetes [10]?
Still inconclusive evidence suggests that early renal abnor-
malities may be linked to overt nephropathy by one or more of
the following hypothetical mechanisms that are also involved in
the early hyperfunction-hypertrophy: (1) The increase in base-
ment membrane material, in association with the increase in
filtration surface area, could be regarded as a forerunner of the
later demonstrable increase in basement membrane matrix, first
noted as thickening and eventually productive of clinical
nephropathy [8, 9]. (2) Hemodynamic changes, predominantly
an increased filtration pressure, may also be operative in
producing glomerular lesions. Suggestive evidence in support of
such a mechanism is obtained in the rat model [11]. (3)
Abnormal extravasation of plasma proteins as a function of
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poor metabolic control may also be of pathogenetic importance
[121.
That hemodynamic mechanisms serve as a modulating influ-
ence rather than as a fundamental determinant of the develop-
ment of nephropathy is indicated by the facts that (I) rats with
severe diabetes mellitus do not show the characteristic hemody-
namic changes [11, 13], but nevertheless, they do develop
unambiguous basement membrane thickening; (2) lesions re-
sembling diabetic glomerulopathy are not reported in man or
animals after unilateral nephrectomy, a condition with similar-
ities to the early hypertrophy-hyperfunction syndrome; (3)
diabetic microangiopathy is found in all organs, despite their
differing physiological and morphological characteristics; renal
lesions develop in type 2 diabetes where hyperfiltration seems
not to occur.
The determinants for the elevated glomerular filtration rate
(GFR) in early diabetes mellitus have been studied using
morphometry and physiological methods in both man and
experimental animals (Table 2). The relationship between form
and function is likely to be complex; initiating factors and
mechanisms are especially difficult to define. Careful studies in
transition phases, before steady state hyperfunction-hypertro-
phy has been achieved, are needed to solve these problems.
The available evidence suggests that the filtration apparatus is
expanded concomitant with increased filtration pressure and
plasma flow, the latter at least when studied in the Munich-
Wistar rat [11, 13]. However, extrapolation to other species and
to human physiology, not to mention to disease, confronts the
investigators with very real interpretative problems [14].
Hyperglycemia per se is likely to predominate both in initiat-
ing and maintaining the abnormalities, while other factors such
as glucagon or growth hormone may act as modulating factors
[15—17].
A suitable animal model is still needed for diabetic nephrop-
athy so that a number of therapeutical maneuvers can be
evaluated: A model is needed that exhibits early hypertrophy-
hyperfunction, and subsequently develops basement membrane
thickening and late glomerulosclerosis with marked proteinuria,
hypertension, and declining kidney function. The streptozoto-
cm model in the rat mimics the early course with hypertrophy
and later basement membrane thickening, although the late
diabetic nephropathy syndrome does not develop, perhaps due
to the short life span of this animal.
From the clinical point of view, we are still faced with the
puzzling phenomenon that clinically significant diabetic renal
disease develops only in about one third of the patients with
juvenile onset diabetes. Apart from the quality of metabolic
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4 Long-term diabetic
nephropathy (a clinical
diagnosis)
Table 1. The kidney in human diabetes
Time to develop
Days or weeks, still pres-
ent after many years
when control imperfect
>2 years, progression
with time
Main features
Kidney hypertrophy-hy-
perfunction exercise-
microalbuminuria
Increased basement mem-
brane thickness and
mesangial enlargement
Slight or intermittent pro-
teinuria, and incipient
blood pressure increase.
Aggravation during ex-
ercise [20]
Persistent proteinuriab and
diabetes of long dura-
tion associated with a
decline in GFR and
hypertension
Reversible or arrestable
by strict glycemic
Methods control
Renal function test, mor-
phometry and roentgen-
ographic methods
Renal biopsy
Close clinical and labora-
tory observation: exer-
cise provocation test
Probably not arrestable
hut studies are going on
[23]: ameliorated by
antihypertensive treat-
ment [9. 20]
Comparable diabetes
Human diabetes in rats
RPF
RPF/kidney weight
3 Plasma oncotic pressure
Filtration pressure
Filtration area
Hydraulic conductance
N = normal.
albumin +lOO%.i
excretion N-
control throughout the years [181. neither protecting nor aggra-
vating factors have been defined clearly [101. although hyper-
tension late in the course seems to be a major risk factor in
juvenile onset insulin-dependent diabetic patients [191. The
important phase of incipient diabetic nephropathy, after 10 to 15
years of disease, is evidenced by a small or a ten- to twenty-fold
increase in baseline albumin excretion, aggravated during the
exercise provocation test [20]. In this stage of development
before the decline in filtration rate, great effort should be taken
in clinical trials to clarify whether or not the course may be
altered, that is, can the fall in kidney function be prevented or
markedly postponed by manipuktting the two factors known to
influence kidney function in diabetic man: the glycemic-hor-
monal state and the blood pressure level [9, 20].
Although great advances in the treatment of end-stage renal
failure in diabetic patients have now been achieved with dialysis
and transplantation [31, it seems the future emphasis should
focus on the discovery of preventative measures. One logical
course is careful metabolic control throughout the life of
diabetic patients. Therefore, it is hoped that the new conceptual
and technological breakthrough with the portable subcutaneous
insulin devices [2 1—23] will offer further practical improve-
ments. It is also hoped that long-term studies will be carefully
conducted in the immediate future to evaluate when and how,
and in which patients, the new methods should be used.
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Chronology or stages
1 Very early renal
involvement
2 Diabetic kidney lesions
3 Clinical incipient
nephropathy
10 to IS years (with
great variation)
>10 to 20 years (with
great variation)
Reversible
Stage I changes at least
partially reversible:
Stage 2 probably not
Studies in progress
Different mechanisms likely to be operative in the early and in the late course.
Exclude other causes in an atypical development.
Close clinical and labora-
tory observation: renal
function monitoring
Onset of Clinical Insulin Standard Proteinuria: fall in GFR
Function diabetes diagnosis treatment control (+ increase in blood pressure)
i Non-proteinuric pasiests
GFR
Table 2. Determinants of GFR in early diabetes
Exercise
control ['\L . . . Proteinuria
N
N
9
I9
N
1'
2 2
Stages (see table I) 1 2 3 4
Structure
+100%-
Basement
membrane N-
thickness
Mesangial +100%
regions
Delcine in GFR, proseinuria
D"Weeks "years - -- -
20 25 30
Fig. I. Chronology of renal changes in diabete,s ,nellhtns. Hatch area
indicates SD. (1) Parallel increase in renal size but not in RPF [9]. (2)
Some patients also exhibit abnormally high baseline values in spite of
negative Albustix [23]. (3) Reduced progression during treatment shown
in a small series of patients [20]. (4) Probably wide variation in long-
term diabetic patients. (5) About 359k of patients developed nephrop-
athy according to Danish follow-up studies [10],
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